A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Alabama at Birmingham
Ossium Health, Inc.
NextCure, Inc.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Novartis
University of Arizona
Massachusetts General Hospital
Bristol-Myers Squibb
BlossomHill Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Celgene
Novartis
M.D. Anderson Cancer Center
Cyclacel Pharmaceuticals, Inc.
University of Chicago
Zhujiang Hospital
Weill Medical College of Cornell University
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Baylor College of Medicine
Taiga Biotechnologies, Inc.
Bayer
Cyclacel Pharmaceuticals, Inc.
Icahn School of Medicine at Mount Sinai
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Bellicum Pharmaceuticals
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
University of Miami
Celgene
Daiichi Sankyo
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University College, London
National Cancer Institute (NCI)
University of Maryland, Baltimore
University of Pittsburgh
Dana-Farber Cancer Institute
University of Washington
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Weill Medical College of Cornell University
Traws Pharma, Inc.